NKGen Biotech, Inc. (OTC: NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization ...

Cognition Therapeutics surges 35% after a positive FDA meeting for Alzheimer’s drug zervimesine. Read more here.

The health ministry is expected to cut the official price of the drug by up to 15% from the current level of about ¥3 million ...

We spoke to the first author of a new study that could challenge much of what we thought we knew about Alzheimer’s disease.

Japanese authorities are putting Eisai (TYO: 4523) under pressure to reconsider the price of its Alzheimer’s disease therapy ...

.

A promising new study from the Knight Family DIAN-TU research group at Washington University School of Medicine has found that starting Alzheimer’s treatment years before symptoms begin could delay — ...

A scan that can detect Alzheimer’s disease before memory loss begins is now available in the UAE for the first time. The amyloid PET scan, recently launched at Cleveland Clinic Abu Dhabi, is a ...

Eli Lilly has won a green light from the FDA for new dosing for its Alzheimer's disease therapy Kisunla, which carries a ...

A recent study of patients who developed bipolar disorder or depression later in life revealed that half had high ...

HATFIELD, HERTFORDSHIRE, UNITED KINGDOM (UK), and MAIDENHEAD, UK, 7 JULY 2025 – Eisai Europe Ltd. and Biogen Idec Ltd. announced today that the Scottish Medicines Consortium (SMC) has not recommended ...

Because Alzheimer’s is just one of several diseases that cause dementia, the key distinction lies in their scope. “Alzheimer’s disease is a specific condition resulting from an abnormal biological ...